Education
About Us
Working with TipRanks
Follow Us
DocMorris AG (CH:DOCM)
:DOCM
DOCM Stock Chart & Stats
CHF5.24
CHF0.36(1.86%)
At close: 4:00 PM EST
CHF5.24
CHF0.36(1.86%)
Day’s Range― - ―
52-Week RangeCHF4.79 - CHF12.26
Previous CloseN/A
Volume45.75K
Average Volume (3M)342.18K
Market Cap
CHF252.04M
Enterprise ValueCHF414.93M
Total Cash (Recent Filing)CHF230.29M
Total Debt (Recent Filing)CHF310.55M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Mar 19, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding51,617,825
10 Day Avg. Volume377,518
30 Day Avg. Volume342,178
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.69
Price to Sales (P/S)0.23
P/FCF Ratio-4.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF8.00Price Target Upside52.67% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.65
Revenue Forecast (FY)CHF1.25B
Bulls Say, Bears Say
Bulls Say
Strong Rx Revenue GrowthA 43.5% Rx revenue increase signals durable core business expansion in prescription fulfillment, strengthening recurring, reimbursed sales. This deepens market position, supports scale economics in distribution, and provides a foundation for sustained revenue mix improvements over multiple quarters.
Rapid TeleClinic ExpansionTelemedicine growth >150% diversifies revenue toward higher-margin digital services and improves gross-profit mix; management expects TeleClinic to supply ~10% of 2025 gross profit. Structural telehealth adoption enhances recurring service revenue and competitive moat beyond retail pharmacy.
Successful CHF 200m Capital IncreaseA CHF 200m equity raise with 99% take-up materially improves liquidity and balance-sheet flexibility, reducing near-term refinancing risk. This durable funding supports investment in digital platform rollouts, TeleClinic scale-up and marketing needed to convert product-led growth into longer-term profitability.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow constrain self-funded growth and force reliance on external capital. Over months this limits ability to sustain high marketing and service investments, raises liquidity risk, and lengthens the path to cash-generative operations without structural margin improvement.
Sustained Adjusted EBITDA LossesOngoing negative adjusted EBITDA, exacerbated by elevated marketing spend, indicates the company has not yet converted revenue growth into operating profitability. Structural operational losses strain cash needs and weaken the ability to invest in higher-return initiatives until gross-margin or cost base improvements are sustained.
Decreasing Shareholder EquityA declining equity base reduces the firm’s capital buffer against shocks and increases sensitivity to future losses or operational setbacks. Over the medium term this can necessitate dilution or recurring capital raises, constraining financial flexibility and investor returns unless profitability and retained earnings recover.
DocMorris News
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF4.79 and its highest was CHF12.26 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF252.04M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Mar 19, 2026 which is in 16 days.
How were DocMorris AG’s earnings last quarter?
DocMorris AG released its earnings results on Aug 19, 2025. The company reported -CHF2.11 earnings per share for the quarter, missing the consensus estimate of -CHF1.33 by -CHF0.78.
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate is -1.08.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 51,617,825 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
DocMorris AG reported an EPS of -CHF2.11 in its last earnings report, missing expectations of -CHF1.33. Following the earnings report the stock price went down -11.611%.
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products, as well as medicines management services. It also operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals under the Zur Rose, PromoFarma, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
DOCM Stock 12 Month Forecast
Average Price Target
CHF8.00
▲(52.67% Upside)
Technical Analysis
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Galenica AG
―
Galderma Group AG
―
medmix AG
―
Options Prices
Currently, No data available
---